RBC Capital Markets Initiated Grail Stock Coverage
The firm issued a Sector Perform rating and an $84 price target for the cancer-screening company.
Updated on Sept. 18, 2026 in Cancer
Live Poll
Is now a good time to invest in medical companies developing early cancer detection technologies?
RBC Capital Markets has begun tracking Grail Inc., assigning the firm a Sector Perform rating. The analyst price forecast for the shares stands at $84.
Why it matters
Grail focuses on early detection of malignancies through its Galleri tool, which screens for methylation patterns before physical symptoms emerge. The test targets cancers that currently lack standard screening protocols.
The Galleri screening tool currently connects to 450 health systems through an Epic integration. The potential annual testing market for this technology encompasses over 100 million people in the U.S. and 300 million globally.
The players
Grail Inc.
A healthcare company that develops blood tests for the early detection of multiple types of cancer.
RBC Capital Markets
A global investment bank providing corporate and investment banking services to institutions and individuals.
Epic
A major developer of electronic health record software used by hospitals and clinics worldwide.
The details
Grail recently collaborated with Epic to facilitate access to its cancer-screening results via electronic health records. While the company aims for FDA approval, its NHS-Galleri trial notably failed to meet its primary clinical endpoint.
Timeline
April 2026: Grail announced a strategic collaboration with Epic.
September 17, 2026: RBC Capital Markets initiated coverage on Grail Inc.
September 18, 2026: Shares traded at $80.12.
September 23, 2026: FDA advisory committee meets to discuss the Galleri test.
Late 2026/Early 2027: Potential timeline for FDA approval.
Health Landscape
The development of multi-cancer early detection tests marks a shift in oncology, though companies like Grail face challenges set by the NHS-Galleri trial. Investors remain cautious as the field moves toward FDA review after early clinical data failed to hit benchmarks.
The Epic integration potentially allows patients to access cancer-screening results more easily through their existing healthcare providers. While the test aims to detect malignancies earlier, its clinical efficacy remains subject to ongoing regulatory scrutiny.
The takeaway
The Galleri test represents an attempt to standardize early cancer detection through methylation analysis. Patients should follow upcoming FDA discussions closely to understand how these diagnostics may soon integrate into standard annual checkups.
What happens next
An FDA advisory committee is scheduled to meet on September 23, 2026, to discuss the Galleri screening tool, which may influence regulatory approval in late 2026 or early 2027.
Further reading
For more on the latest research in this field, visit the Cancer section.
Source note: This article includes information reported by Benzinga.
Live Poll
Is now a good time to invest in medical companies developing early cancer detection technologies?
